Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 3Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 56Prostatic Neoplasms, Castration-Resistant 5Neoplasm Metastasis 4Metastatic Castration-resistant Prostate Cancer 4Prostatic Diseases 3Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Male Urogenital Diseases 2Genital Diseases, Male 2Bulbo-Spinal Atrophy, X-Linked 2Biochemically Recurrent Prostate Cancer 2Adenocarcinoma 2Urogenital Neoplasms 1Urogenital Diseases 1Thrombocytosis 1Prostate Cancer Non-Metastatic 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms by Site 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1

Interventions

enzalutamide 6Abiraterone Acetate 6olaparib 5Docetaxel 5darolutamide 4Prednisone 4Pluvicto 4cabazitaxel 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2fludarabine 2abiraterone 2Prednisolone 2Nivolumab 2Cyclophosphamide 2Androgen Antagonists 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1lactitol 1fludarabine phosphate 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1alovudine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Metastatic Castration-resistant Prostate Cancer × darolutamide × Clear all
NCT07244341 2026-05-15

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Daiichi Sankyo

Phase 1 Recruiting
60 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Swiss Cancer Institute

Phase 2 Recruiting
162 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05762536 2024-06-27

DAROTAXEL

Erasmus Medical Center

Phase 2 Recruiting
245 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04237584 2022-10-07

ESCALATE

MANA RBM

Phase 3 Terminated
23 enrolled 11 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡